



Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations

Private Circulation Only

Workshop on

"INNOVATION – The Bridge & Platform for Progress"

at Thiruvananthapuram, Kerala

Shri P.H. Kurian, Addl. Chief Secretary & Revenue Secretary;
Former Controller General of Patents, Designs & Trademarks, Govt. of India
inaugurating and speaking on the occasion



The workshop coincided with the opening of the office of GNAs/GNANLEX at Thiruvananthapuram.

The workshop had emphasis on "INNOVATION - The Bridge & Platform for Progress".

The presentations at the workshop can be made available on request.

Editorial.....


Of late, we and the Nation have been going through an unprecedented "action phase" accompanied by a lot of heat and dust, a lot of heated debates, a lot of dust of confusion bordering a passing phase of chaos, all of these hopefully for a good cause, leading to a better tomorrow and long-term economic benefit. Hopefully the GST dust will settle down sooner with a little help from the government. India has been acclaimed globally for its sweeping reforms, climbing 50 slots higher on the ratings on "Ease of Doing Business". Contrary to the saying "if life appears smooth and cozy all the time, you are going downhill", India and Indian entrepreneurs have been on their toes in 2017, tackling a multitude of procedural changes accompanying major policy initiatives. Multilateral (RCEP for example) and bilateral engagements and negotiations have been in fast track progress, hopefully to improve trade and global communications.

On the Pharma front too, there has been unprecedented action-reaction and proposals-responses, keeping the IDMA office bearers and secretariat on their toes. The joint training program (Advanced Program in Pharmaceutical Quality Management) of IDMA-NSF under the leadership initiative of Dr. S.M. Mudda was a grand success. The RCEP negotiations involving ASEAN and six other nations are moving forward at a good pace. Hopefully, RCEP will become a reality soon without undue provisions of TRIPS plus. September-October, 2017 has seen a lot of action on multiple platforms. A few of these events are covered with brief reports in this issue.

OPPI ANNUAL DAY CELEBRATED THEME – THE ‘DNA OF CARE’



Organisation of Pharmaceutical Producers of India



At the OPPI Annual Day, the emphasis was on innovation for a healthy India and on ease of doing business. On the occasion, a book “DNA of Care” was released. Dr. Srinivasa Reddy of NCL (CSIR) received the Scientist Award 2017, while Dr. Debabrata Maiti of IIT, Bombay received the young Scientist Award 2017

The Central Drugs Standard Control Organization (CDSCO) in collaboration with National Chemical Laboratory (NCL) Pune and Indian Pharmacopoeia Commission (IPC), Raj Nagar, Ghaziabad organized “One Day Interactive Session” on October 11, 2017 at the CSIR- National Chemical Laboratory, Dr. Homi Bhabha Road, Pune



The CDSCO-NCL conference along with the Indian Pharmacopoeia Commission was a grand success. MOU was signed by Dr. G.N. Singh, DCG(I) and Dr. Ashwini Nangia, Director, NCL for synthesising reference standards and standard impurities for support to the IPC's product.

Wadhwani Research Center for Bioengineering (WRCB)

Indian Institute of Technology Bombay


Organized

2ND WRCB INDUSTRY DAY

**Theme : "From Lab to Bedside: Challenges and opportunities in converting Proof of Concept to Product" on September 8th, 2017
at IIT Bombay**



This excellent event was addressed by eminent experts and resource persons such as Dr. Anil Koul, Director, CSIR-IMTech; Dr. Sanjit Singh Lamba, M.D., Eisai Pharmaceuticals and others.



Dr. Habil Khorakiwala's autobiography "ODYSSEY OF COURAGE" – The story of an Indian Multinational – was released in Mumbai, at the Dome, NSCI, Mahalaxmi on 29th October 2017 by Nobel Laureate Dr. Kailash Satyarthi in presence of a large number of luminaries and dignitaries. The even coincided with Dr. Habil's 75th Birthday as well as Wockhardt's 50th Birthday, in its transition from Worli Chemical Works to Wockhardt with the backing from Akabarally's and Dr. Habil's father Mr. Fakhruddin Khorakiwala. Brief speeches by second generation and songs/ performances by third generation (grandchildren of Dr. Habil) made the occasion nostalgic.

The drug discovery program leading to new Antibiotic NCEs from Wockhardt was revealed on the occasion as well as in the Book. It is hoped that one or more of the new Antibiotics on anvil WCK 4873, WCK 5272 and WCK 4282, will be approved as NCEs by USFDA by 2020/2021. We wish Wockhardt, Dr.Habil, the Khorakiwala family and the NDA/NCE program all success.